Last $12.92 USD
Change Today -0.34 / -2.56%
Volume 204.2K
SRNE On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 5:20 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

sorrento therapeutics inc (SRNE) Snapshot

Open
$13.30
Previous Close
$13.26
Day High
$13.30
Day Low
$12.57
52 Week High
03/21/14 - $16.40
52 Week Low
10/14/14 - $3.10
Market Cap
468.0M
Average Volume 10 Days
285.8K
EPS TTM
$-1.83
Shares Outstanding
36.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SORRENTO THERAPEUTICS INC (SRNE)

Related News

No related news articles were found.

sorrento therapeutics inc (SRNE) Related Businessweek News

No Related Businessweek News Found

sorrento therapeutics inc (SRNE) Details

Sorrento Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary drug therapeutics for addressing unmet medical needs in the United States, Europe, and internationally. Its lead product candidate, Cynviloq, is a micellar diblock copolymeric paclitaxel formulation currently approved and marketed in various countries, including South Korea, for metastatic breast cancer (MBC), non-small cell lung cancer (NSCLC), and ovarian cancer under the trade name Genexol-PM. Cynviloq has also completed Phase I or III trials for MBC, and Phase I or II trials in NSCLC, Ovarian, Bladder, and Pancreatic cancers. The company is also developing resiniferatoxin, a non-opiate, ultra potent and selective agonist of the TRPV-1 receptor for intractable pain in end-stage disease. In addition, the company is also developing antibody drug conjugates and recombinant intravenous immunoglobulin (rIVIG) for the treatment of certain auto-immune diseases, as well as immunodeficiencies. Sorrento Therapeutics, Inc. was founded in 2006 and is based in San Diego, California.

50 Employees
Last Reported Date: 04/1/14
Founded in 2006

sorrento therapeutics inc (SRNE) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $291.4K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $296.0K
Compensation as of Fiscal Year 2013.

sorrento therapeutics inc (SRNE) Key Developments

Sorrento Therapeutics, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015

Sorrento Therapeutics, Inc. Presents at Biocom's Global Life Science Partnering Conference, Feb-25-2015 . Venue: The Lodge at Torrey Pines, 11480 North Torrey Pines Road, La Jolla, CA 92037, United States.

Sorrento Therapeutics, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 05:30 PM

Sorrento Therapeutics, Inc. Presents at 17th Annual BIO CEO & Investor Conference, Feb-09-2015 05:30 PM. Venue: The Waldorf Astoria, New York, New York, United States.

Sorrento Therapeutics, Inc. Announces Completion of Enrollment in the Cynviloq Registrational TRIBECA Study

Sorrento Therapeutics, Inc. announced that the last patient in (total n = 111 patients) has been randomized in the ongoing TRIBECA (TRIal establishing bioequivalence [BE] between Cynviloq and Albumin-bound paclitaxel) registrational trial. Patients were enrolled globally from sites in USA, Eastern Europe, and Asia. The ongoing safety assessment from treated patients continues to reveal no unexpected adverse events and the data is consistent with the toxicity profile reported in the literature with albumin-bound paclitaxel. Previously, Sorrento announced positive pharmacokinetic (PK) data from the first eight (8) patients enrolled in the TRIBECA study.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SRNE:US $12.92 USD -0.34

SRNE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SRNE.
View Industry Companies
 

Industry Analysis

SRNE

Industry Average

Valuation SRNE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 120.2x
Price/Book 5.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 134.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SORRENTO THERAPEUTICS INC, please visit www.sorrentotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.